Functional characterization of the brain-to-blood efflux clearance of human amyloid-β peptide (1-40) across the rat blood-brain barrier

Neuroscience Research

Volumn 56, Issue 3, 2006, Pages 246-252

  Ito, Shingo ^a   Ohtsuki, Sumio ^a,b   Terasaki, Tetsuya ^a,b  

^a TOHOKU UNIVERSITY   (Japan)

^b Japan Science and Technology Agency   (Japan)

Author keywords

A degrading enzyme; Alzheimer's disease; Efflux transport; Gender difference; LRP 1; P gp

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; ENDOTHELIN CONVERTING ENZYME; GLYCOPROTEIN P; GLYCOPROTEIN P INHIBITOR; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; PROTEIN INHIBITOR; QUINIDINE; VERAPAMIL;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN CAPILLARY; BRAIN SLICE; CAPILLARY ENDOTHELIUM; CONTROLLED STUDY; ENZYME DEGRADATION; FEMALE; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN TRANSPORT; RAT; SEX DIFFERENCE; STATISTICAL SIGNIFICANCE; WESTERN BLOTTING;

AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN; ANIMALS; BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; BRAIN; FEMALE; GENE EXPRESSION; HUMANS; IODINE ISOTOPES; MALE; P-GLYCOPROTEIN; PEPTIDE FRAGMENTS; RATS; RATS, SPRAGUE-DAWLEY; TIME FACTORS; TUMOR SUPPRESSOR PROTEINS;

EID: 33750017850     PISSN: 01680102     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neures.2006.07.006     Document Type: Article

References (43)

1. Andersen K., Launer L.J., Dewey M.E., Letenneur L., Ott A., Copeland J.R., Dartigues J.F., Kragh-Sorensen P., Baldereschi M., Brayne C., et al. Gender differences in the incidence of AD and vascular dementia: The EURODEM Studies. EURODEM Incidence Research Group. Neurology 53 (1999) 1992-1997
2. Bayer T.A., Schafer S., Simons A., Kemmling A., Kamer T., Tepest R., Eckert A., Schussel K., Eikenberg O., Sturchler-Pierrat C., Abramowski D., Staufenbiel M., and Multhaup G. Dietary Cu stabilizes brain superoxide dismutase 1 activity and reduces amyloid Aβ production in APP23 transgenic mice. Proc. Natl. Acad. Sci. U.S.A. 100 (2003) 14187-14192
3. Callahan M.J., Lipinski W.J., Bian F., Durham R.A., Pack A., and Walker L.C. Augmented senile plaque load in aged female β-amyloid precursor protein-transgenic mice. Am. J. Pathol. 158 (2001) 1173-1177
4. Cirrito J.R., May P.C., O'Dell M.A., Taylor J.W., Parsadanian M., Cramer J.W., Audia J.E., Nissen J.S., Bales K.R., Paul S.M., DeMattos R.B., and Holtzman D.M. In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-β metabolism and half-life. J. Neurosci. 23 (2003) 8844-8853
5. Cirrito J.R., Deane R., Fagan A.M., Spinner M.L., Parsadanian M., Finn M.B., Jiang H., Prior J.L., Sagare A., Bales K.R., et al. P-glycoprotein deficiency at the blood-brain barrier increases amyloid-β deposition in an Alzheimer disease mouse model. J. Clin. Invest. 115 (2005) 3285-3290
6. Deane R., Du Y.S., Submamaryan R.K., LaRue B., Jovanovic S., Hogg E., Welch D., Manness L., Lin C., Yu J., et al. RAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brain. Nat. Med. 9 (2003) 907-913
7. Deane R., Wu Z., Sagare A., Davis J., Du Y.S., Hamm K., Xu F., Parisi M., LaRue B., Hu H.W., et al. LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. Neuron 43 (2004) 333-344
8. DeMattos R.B., Bales K.R., Parsadanian M., O'Dell M.A., Foss E.M., Paul S.M., and Holtzman D.M. Plaque-associated disruption of CSF and plasma amyloid-beta (Abeta) equilibrium in a mouse model of Alzheimer's disease. J. Neurochem. 81 (2002) 229-236
9. Eckman E.A., Reed D.K., and Eckman C.B. Degradation of the Alzheimer's amyloid beta peptide by endothelin-converting enzyme. J. Biol. Chem. 276 (2001) 24540-24548
10. Eckman E.A., Watson M., Marlow L., Sambamurti K., and Eckman C.B. Alzheimer's disease β-amyloid peptide is increased in mice deficient in endothelin-converting enzyme. J. Biol. Chem. 278 (2003) 2081-2084
11. Farris W., Mansourian S., Chang Y., Lindsley L., Eckman E.A., Frosch M.P., Eckman C.B., Tanzi R.E., Selkoe D.J., and Guenette S. Insulin-degrading enzyme regulates the levels of insulin, amyloid β protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc. Natl. Acad. Sci. U.S.A. 100 (2003) 4162-4167
12. Field P.A., and Gibbons G.F. Decreased hepatic expression of the low-density lipoprotein (LDL) receptor and LDL receptor-related protein in aging rats is associated with delayed clearance of chylomicrons from the circulation. Metabolism 49 (2000) 492-498
13. Fratiglioni L., Viitanen M., von Strauss E., Tontodonati V., Herlitz A., and Winblad B. Very old women at highest risk of dementia and Alzheimer's disease: incidence data from the Kungsholmen Project, Stockholm. Neurology 48 (1997) 132-138
14. Ghiso J., Shayo M., Calero M., Ng D., Tomidokoro Y., Gandy S., Rostagno A., and Frangione B. Systemic catabolism of Alzheimer's Aβ40 and Aβ42. J. Biol. Chem. 279 (2004) 45897-45908
15. Hardy J., and Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297 (2002) 353-356
16. Hosoya K., Tetsuka K., Nagase K., Tomi M., Saeki S., Ohtsuki S., Takanaga H., Yanai N., Obinata M., Kikuchi A., Okano T., and Terasaki T. Conditionally immortalized brain capillary endothelial cell lines established from a transgenic mouse harboring temperature-sensitive simian virus 40 large T-antigen gene. AAPS PharmSci. 2 (2000) E27
17. Iwata N., Tsubuki S., Takaki Y., Shirotani K., Lu B., Gerard N.P., Gerard C., Hama E., Lee H.J., and Saido T.C. Metabolic regulation of brain Aβ by neprilysin. Science 292 (2001) 1550-1552
18. Joslin G., Krause J.E., Hershey A.D., Adams S.P., Fallon R.J., and Perlmutter D.H. Amyloid-β peptide, substance P, and bombesin bind to the serpin-enzyme complex receptor. J. Biol. Chem. 266 (1991) 21897-21902
19. Kakee A., Terasaki T., and Sugiyama Y. Brain efflux index as a novel method of analyzing efflux transport at the blood-brain barrier. J. Pharmacol. Exp. Ther. 277 (1996) 1550-1559
20. Kandimalla K.K., Curran G.L., Holasek S.S., Gilles E.J., Wengenack T.M., and Poduslo J.F. Pharmacokinetic analysis of the blood-brain barrier transport of 125I-amyloid beta protein 40 in wild-type and Alzheimer's disease transgenic mice (APP, PS1) and its implications for amyloid plaque formation. J. Pharmacol. Exp. Ther. 313 (2005) 1370-1378
21. Kang D.E., Saitoh T., Chen X., Xia Y., Masliah E., Hansen L.A., Thomas R.G., Thal L.J., and Katzman R. Genetic association of the low-density lipoprotein receptor-related protein gene (LRP), an apolipoprotein E receptor, with late-onset Alzheimer's disease. Neurology 49 (1997) 56-61
22. Kurochkin I.V. Amyloidogenic determinant as a substrate recognition motif of insulin-degrading enzyme. FEBS Lett. 427 (1998) 153-156
23. Kusuhara H., Suzuki H., Terasaki T., Kakee A., Lemaire M., and Sugiyama Y. P-glycoprotein mediates the efflux of quinidine across the blood-brain barrier. J. Pharmacol. Exp. Ther. 283 (1997) 574-580
24. Lam F.C., Liu R., Lu P., Shapiro A.B., Renoir J.M., Sharom F.J., and Reiner P.B. β-Amyloid efflux mediated by p-glycoprotein. J. Neurochem. 76 (2001) 1121-1128
25. Martel C.L., Mackic J.B., Matsubara E., Governale S., Miguel C., Miao W., McComb J.G., Frangione B., Ghiso J., and Zlokovic B.V. Isoform-specific effects of apolipoproteins E2, E3, and E4 on cerebral capillary sequestration and blood-brain barrier transport of circulating Alzheimer's amyloid β. J. Neurochem. 69 (1997) 1995-2004
26. Matter M.L., Zhang Z., Nordstedt C., and Ruoslahti E. The α5β1 integrin mediates elimination of amyloid-β peptide and protects against apoptosis. J. Cell. Biol. 141 (1998) 1019-1030
27. May P., Bock H.H., Nimpf J., and Herz J. Differential glycosylation regulates processing of lipoprotein receptors by γ-secretase. J. Biol. Chem. 278 (2003) 37386-37392
28. Mori S., Ohtsuki S., Takanaga H., Kikkawa T., Kang Y.S., and Terasaki T. Organic anion transporter 3 is involved in the brain-to-blood efflux transport of thiopurine nucleobase analogs. J. Neurochem. 90 (2004) 931-941
29. Poduslo J.F., Curran G.L., Wengenack T.M., Malester B., and Duff K. Permeability of proteins at the blood-brain barrier in the normal adult mouse and double transgenic mouse model of Alzheimer's disease. Neurobiol. Dis. 8 (2001) 555-567
30. Schuessel K., Schafer S., Bayer T.A., Czech C., Pradier L., Muller-Spahn F., Muller W.E., and Eckert A. Impaired Cu/Zn-SOD activity contributes to increased oxidative damage in APP transgenic mice. Neurobiol. Dis. 18 (2005) 89-99
31. Seeman M.V. Psychopathology in women and men: focus on female hormones. Am. J. Psychiatr. 154 (1997) 1641-1647
32. Shibata M., Yamada S., Kumar S.R., Calero M., Bading J., Frangione B., Holtzman D.M., Miller C.A., Strickland D.K., Ghiso J., and Zlokovic B.V. Clearance of Alzheimer's amyloid-β(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J. Clin. Invest. 106 (2000) 1489-1499
33. Shiiki T., Ohtsuki S., Kurihara A., Naganuma H., Nishimura K., Tachikawa M., Hosoya K., and Terasaki T. Brain insulin impairs amyloid-β(1-40) clearance from the brain. J. Neurosci. 24 (2004) 9632-9637
34. Tamaki, C., Ohtsuki, S., Iwatsubo, T., Hashimoto, T., Yamada, K., Yabuki, C., Terasaki, T., 2006. Major involvement of low-density lipoprotein receptor-related protein 1 in the clearance of plasma free amyloid β-peptide by the liver. Pharm. Res. 23 1407-1416.
35. Terasaki T., and Ohtsuki S. Brain-to-blood transporters for endogenous substrates and xenobiotics at the blood-brain barrier: an overview of biology and methodology. NeuroRx 2 (2005) 63-72
36. Van Uden E., Mallory M., Veinbergs I., Alford M., Rockenstein E., and Masliah E. Increased extracellular amyloid deposition and neurodegeneration in human amyloid precursor protein transgenic mice deficient in receptor-associated protein. J. Neurosci. 22 (2002) 9298-9304
37. Vogelgesang S., Cascorbi I., Schroeder E., Pahnke J., Kroemer H.K., Siegmund W., Kunert-Keil C., Walker L.C., and Warzok R.W. Deposition of Alzheimer's β-amyloid is inversely correlated with P-glycoprotein expression in the brains of elderly non-demented humans. Pharmacogenetics 12 (2002) 535-541
38. Wang J., Tanila H., Puolivali J., Kadish I., and van Groen T. Gender differences in the amount and deposition of amyloid β in APPswe and PS1 double transgenic mice. Neurobiol. Dis. 14 (2003) 318-327
39. Warshawsky I., Bu G., and Schwartz A.L. 39-kD protein inhibits tissue-type plasminogen activator clearance in vivo. J. Clin. Invest. 92 (1993) 937-944
40. Wengenack T.M., Curran G.L., and Poduslo J.F. Targeting Alzheimer amyloid plaques in vivo. Nat. Biotechnol. 18 (2000) 868-872
41. Xie L., Helmerhorst E., Taddei K., Plewright B., Van Bronswijk W., and Martins R. Alzheimer's β-amyloid peptides compete for insulin binding to the insulin receptor. J. Neurosci. 22 (2002) RC221
42. Yamaoka K., Tanigawara Y., Nakagawa T., and Uno T. A pharmacokinetic analysis program (multi) for microcomputer. J. Pharmacobiodyn. 4 (1981) 879-885
43. Zhang Y., and Pardridge W.M. Rapid transferrin efflux from brain to blood across the blood-brain barrier. J. Neurochem. 76 (2001) 1597-1600